OBJECTIVE: To investigate the mechanisms by which macrophage scavenger receptor BI (SR-BI) regulates macrophage cholesterol homeostasis and protects against atherosclerosis. METHODS AND RESULTS: The expression and function of SR-BI was investigated in cultured mouse bone marrow-derived macrophages (BMM). SR-BI, the other scavenger receptors SRA and CD36 and the ATP-binding cassette transporters ABCA1 and ABCG1 were each distinctly regulated during BMM differentiation. SR-BI levels increased transiently to significant levels during culture. SR-BI expression in BMM was reversibly down-regulated by lipid loading with modified LDL; SR-BI was shown to be present both on the cell surface as well as intracellularly. BMM exhibited selective HDL CE uptake, however, this was not dependent on SR-BI or another potential candidate glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 (GPIHBP1). SR-BI played a significant role in facilitating bidirectional cholesterol flux in non lipid-loaded cells. SR-BI expression enhanced both cell cholesterol efflux and cholesterol influx from HDL, but did not lead to altered cellular cholesterol mass. SR-BI-dependent efflux occurred to larger HDL particles but not to smaller HDL(3). Following cholesterol loading, ABCA1 and ABCG1 were up-regulated and served as the major contributors to cholesterol efflux, while SR-BI expression was down-regulated. CONCLUSION: Our results suggest that SR-BI plays a significant role in macrophage cholesterol flux that may partly account for its effects on atherogenesis. Published by Elsevier Ireland Ltd.
OBJECTIVE: To investigate the mechanisms by which macrophage scavenger receptor BI (SR-BI) regulates macrophage cholesterol homeostasis and protects against atherosclerosis. METHODS AND RESULTS: The expression and function of SR-BI was investigated in cultured mouse bone marrow-derived macrophages (BMM). SR-BI, the other scavenger receptors SRA and CD36 and the ATP-binding cassette transporters ABCA1 and ABCG1 were each distinctly regulated during BMM differentiation. SR-BI levels increased transiently to significant levels during culture. SR-BI expression in BMM was reversibly down-regulated by lipid loading with modified LDL; SR-BI was shown to be present both on the cell surface as well as intracellularly. BMM exhibited selective HDL CE uptake, however, this was not dependent on SR-BI or another potential candidate glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 (GPIHBP1). SR-BI played a significant role in facilitating bidirectional cholesterol flux in nonlipid-loaded cells. SR-BI expression enhanced both cell cholesterol efflux and cholesterol influx from HDL, but did not lead to altered cellular cholesterol mass. SR-BI-dependent efflux occurred to larger HDL particles but not to smaller HDL(3). Following cholesterol loading, ABCA1 and ABCG1 were up-regulated and served as the major contributors to cholesterol efflux, while SR-BI expression was down-regulated. CONCLUSION: Our results suggest that SR-BI plays a significant role in macrophage cholesterol flux that may partly account for its effects on atherogenesis. Published by Elsevier Ireland Ltd.
Authors: I S Yuhanna; Y Zhu; B E Cox; L D Hahner; S Osborne-Lawrence; P Lu; Y L Marcel; R G Anderson; M E Mendelsohn; H H Hobbs; P W Shaul Journal: Nat Med Date: 2001-07 Impact factor: 53.440
Authors: Anne Braun; Bernardo L Trigatti; Mark J Post; Kaori Sato; Michael Simons; Jay M Edelberg; Robert D Rosenberg; Mark Schrenzel; Monty Krieger Journal: Circ Res Date: 2002-02-22 Impact factor: 17.367
Authors: P G Yancey; M de la Llera-Moya; S Swarnakar; P Monzo; S M Klein; M A Connelly; W J Johnson; D L Williams; G H Rothblat Journal: J Biol Chem Date: 2000-11-24 Impact factor: 5.157
Authors: A Venkateswaran; B A Laffitte; S B Joseph; P A Mak; D C Wilpitz; P A Edwards; P Tontonoz Journal: Proc Natl Acad Sci U S A Date: 2000-10-24 Impact factor: 11.205
Authors: Corine Martineau; Louise Martin-Falstrault; Louise Brissette; Robert Moreau Journal: Am J Physiol Endocrinol Metab Date: 2013-11-19 Impact factor: 4.310